• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>International Journal of Molecular Epidemiology and Genetics >Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study
【2h】

Epidermal growth factor receptor (EGFR) polymorphisms and breast cancer among Hispanic and non-Hispanic white women: the Breast Cancer Health Disparities Study

机译：西班牙裔和非西班牙裔白人女性中的表皮生长因子受体（EGFR）多态性与乳腺癌：乳腺癌健康差异研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, functions in cellular processes essential to the development of cancer. Overexpression of EGFR in primary breast tumors has been linked with poor prognosis. We investigated the associations between 34 EGFR tagging SNPs and breast cancer risk and breast cancer-specific mortality in 4,703 Hispanic and 3,030 non-Hispanic white women from the Breast Cancer Health Disparities Study. We evaluated associations with risk of breast cancer defined by estrogen/progesterone receptor (ER/PR) tumor phenotype. Only one association remained statistically significant after adjusting for multiple comparisons. Rs2075112GA/AA was associated with reduced risk for ER-/PR+ tumor phenotype (odds ratio (OR), 0.34; 95% confidence interval (CI) 0.18-0.63, p adj=0.01). All additional results were significant prior to adjustment for multiple comparisons. Two of the EGFR polymorphisms were associated with breast cancer risk in the overall study population (rs11770531TT: OR, 0.56, 95% CI 0.37-0.84; and rs2293348AA: OR, 1.20, 95% CI 1.04-1.38) and two polymorphisms were associated with risk among Hispanics: rs6954351AA: OR, 2.50, 95% CI 1.32-4.76; and rs845558GA/AA: OR, 1.15, 95% CI 1.01-1.30. With regard to breast cancer-specific mortality, we found positive associations with rs6978771TT hazard ratio (HR), 1.68; 95% CI 1.11-2.56; rs9642391CC HR, 1.64; 95% CI 1.04-2.58; rs4947979AG/GG HR, 1.36; 95% CI 1.03-1.79; and rs845552GG HR, 1.62; 95% CI 1.05-2.49. Our findings provide additional insight for the role of EGFR in breast cancer development and prognosis. Further research is needed to elucidate EGFR’s contribution to ethnic disparities in breast cancer.
机译：表皮生长因子受体（EGFR）是受体酪氨酸激酶ErbB家族的成员，在癌症发展所必需的细胞过程中起作用。 EGFR在原发性乳腺肿瘤中的过表达与不良预后有关。我们从乳腺癌健康差异研究中调查了4,703名西班牙裔和3,030名非西班牙裔白人女性中34种EGFR标签SNP与乳腺癌风险和乳腺癌特异性死亡率之间的关联。我们评估了雌激素/孕激素受体（ER / PR）肿瘤表型与乳腺癌风险的关联。调整多个比较后，只有一个关联在统计上仍然显着。 Rs2075112GA / AA与ER- / PR +肿瘤表型的风险降低相关（几率（OR）为0.34; 95％置信区间（CI）为0.18-0.63，p adj = 0.01）。在进行多次比较调整之前，所有其他结果都很显着。在整个研究人群中，两种EGFR多态性与乳腺癌风险相关（rs11770531TT：OR，0.56，95％CI 0.37-0.84； rs2293348AA：OR，1.20，95％CI 1.04-1.38），两种多态性与西班牙裔风险：rs6954351AA：或为2.50，95％CI为1.32-4.76；和rs845558GA / AA：OR，1.15、95％CI 1.01-1.30。关于乳腺癌的特异性死亡率，我们发现与rs6978771TT危险比（HR）为1.68正相关； 95％CI 1.11-2.56； rs9642391CC HR，1.64； 95％CI 1.04-2.58; rs4947979AG / GG HR，1.36； 95％CI 1.03-1.79;和rs845552GG HR，1.62； 95％CI 1.05-2.49。我们的发现为EGFR在乳腺癌发展和预后中的作用提供了更多的见解。需要进一步研究阐明EGFR对乳腺癌种族差异的贡献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号